An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline.
about
Pirfenidone in the treatment of idiopathic pulmonary fibrosis: an evidence-based review of its place in therapyTherapeutic Approach to Adult Fibrotic Lung DiseasesRecent advances in understanding idiopathic pulmonary fibrosisCardiac manifestations of idiopathic pulmonary fibrosisPharmacological management of IPFPatient considerations and drug selection in the treatment of idiopathic pulmonary fibrosisSleep apnoeaNew perspectives on management of idiopathic pulmonary fibrosisYear in review 2015: Interstitial lung disease, pulmonary vascular disease, pulmonary function, sleep and ventilation, cystic fibrosis and paediatric lung diseasePharmacological Treatment of Idiopathic Pulmonary Fibrosis: Current Approaches, Unsolved Issues, and Future PerspectivesIdiopathic pulmonary fibrosis: current treatment options and critical appraisal of nintedanibManaging comorbidities in idiopathic pulmonary fibrosisIdiopathic Pulmonary Fibrosis: Treatment and PrognosisReal World Experiences: Pirfenidone and Nintedanib are Effective and Well Tolerated Treatments for Idiopathic Pulmonary FibrosisHigh-density Lipoproteins and Apolipoprotein A-I: Potential New Players in the Prevention and Treatment of Lung DiseaseUpdate on diagnosis and treatment of idiopathic pulmonary fibrosisPleural inhibition of the caspase-1/IL-1β pathway diminishes profibrotic lung toxicity of bleomycinPrognostic factors of idiopathic inflammatory myopathies complicated with interstitial lung disease: protocol for a systematic review and meta-analysisAdherence to guidelines in idiopathic pulmonary fibrosis: a follow-up national surveyClinical highlights from AmsterdamImpact of lymphocyte differential count > 15% in BALF on the mortality of patients with acute exacerbation of chronic fibrosing idiopathic interstitial pneumoniaFirst Data on Efficacy and Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis and Forced Vital Capacity of ≤50 % of Predicted Value.MMP-7 is a predictive biomarker of disease progression in patients with idiopathic pulmonary fibrosisPulmonary arterial wall disease in COPD and interstitial lung diseases candidates for lung transplantation.Degree of dyspnoea at admission and discharge in patients with heart failure and respiratory diseases.Idiopathic pulmonary fibrosis in East Asian.Antacid Therapy and Disease Progression in Patients with Idiopathic Pulmonary Fibrosis Who Received Pirfenidone.Protective and therapeutic effect of felodipine against bleomycin-induced pulmonary fibrosis in mice.Fibrotic Hypersensitivity Pneumonitis: Key Issues in Diagnosis and Management.Treatment of connective tissue disease-associated interstitial lung disease: the pulmonologist's point of view.Health related quality of life in patients with idiopathic pulmonary fibrosis in clinical practice: insights-IPF registryThe diagnosis of idiopathic pulmonary fibrosis: current and future approaches.The need for patient-centred clinical research in idiopathic pulmonary fibrosisIdiopathic pulmonary fibrosis in BRIC countries: the cases of Brazil, Russia, India, and China.Change in forced vital capacity and associated subsequent outcomes in patients with newly diagnosed idiopathic pulmonary fibrosis.Evaluating the interstitial lung disease multidisciplinary meeting: a survey of expert centres.Treatment of idiopathic pulmonary fibrosis: a network meta-analysis.Idiopathic pulmonary fibrosis - clinical management guided by the evidence-based GRADE approach: what arguments can be made against transparency in guideline development?End-of-life care of patients with idiopathic pulmonary fibrosis.Double-Blind Randomized Trial of Pirfenidone in Chinese Idiopathic Pulmonary Fibrosis Patients
P2860
Q26738458-750EF0B7-7F37-4D96-8B03-A16BC9602C63Q26741569-15412A0D-4020-4C64-B422-769486E85794Q26745905-92EC20A6-A71C-4F6E-90A2-DF94014DB8DFQ26748176-7ADC1075-989B-44D3-B91D-8225E50409EDQ26748808-38C490DE-7E5E-4989-8B4F-1923C9A4134EQ26750418-2D7A46E2-BF39-45DA-9FCD-2E7B40930B64Q26765374-AE18F3FA-183A-4BCD-89F1-BA8C93DC96C3Q26765586-7AF09655-4F8E-4292-A302-3C1082359582Q26766313-E48D5185-AD7D-41F7-99EE-E1F12EA690CEQ26771309-E45973AF-2924-4252-8D97-B7BA646DDD6AQ26771647-58DE0316-78AB-43A1-83C8-253705A179B4Q26785617-9E29D898-8DED-47C0-B2C1-5AB5010A08B7Q28073641-4A20D8A9-7BBD-48EF-A05D-CA593CC547ACQ28075536-A5BF0265-DBB7-4F65-B334-DC82DBBC81B2Q28075541-73203FD5-BABC-46BD-91C8-EF0FEFE3DFDFQ28083702-34F803F8-8D36-4C77-9B2E-FBD1AECA81D4Q28395139-50B9B1E7-D16B-48E4-A719-E8C0A351296DQ28395250-2A045D64-DCFC-46C8-815F-3DCE18EC047EQ28596805-4F4A4550-9105-459F-831D-3D7D218A4AC7Q28598394-FB2A2B2D-DB55-462B-961D-5CC73076BE07Q30846353-A89C59FA-5573-4353-91CD-26A27F23960AQ31112375-A19D9150-E6CD-46A7-9669-7FC4A6019B06Q33574837-6072DA93-EFE3-4F82-914F-EA001E224DFCQ33645372-8745CB70-F297-4320-A4D9-BEC73F54494EQ33717352-3FD1EF32-E4D5-411C-A406-AC17831E610AQ33747908-70E658D7-E1FE-4506-864F-16A734BFADA4Q33749957-0DB86EA1-B062-40C0-816D-2F52FAD4ADDAQ33794090-A5DBAA1B-163F-4BD8-AC3B-77B5F315D9C6Q33832724-A9EB0625-6C31-4334-B5B3-68616549E9A8Q33907242-99BD3A12-5E70-414C-BE8D-78B8B274A758Q33908569-5C523218-CD29-47F0-9BAA-D0A2E21E0858Q33924950-C2199F97-9236-432E-93D1-16D57C9EC3C0Q35785546-CA0898E4-4950-4D8F-9B4F-B7F9C1FF358DQ35785834-C157E767-483C-44FA-A5FB-D9548959EEF4Q35880972-9BBAFA97-48F2-43B8-8CE6-57D3E181A21BQ35910593-971D39CF-E016-410C-ADD8-667AEA974F36Q35914125-362207CF-2993-4901-BA1C-310478F2AADDQ35918745-488AE267-0351-4A55-B075-05007648E9CEQ36160843-FD537F6C-C906-40BD-AF76-9A049040777EQ36207187-D278DFB3-A4DF-4F42-9EFC-8EE9CE9453E6
P2860
An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh-hant
name
An Official ATS/ERS/JRS/ALAT C ...... 1 Clinical Practice Guideline.
@en
An Official ATS/ERS/JRS/ALAT C ...... 1 Clinical Practice Guideline.
@nl
type
label
An Official ATS/ERS/JRS/ALAT C ...... 1 Clinical Practice Guideline.
@en
An Official ATS/ERS/JRS/ALAT C ...... 1 Clinical Practice Guideline.
@nl
prefLabel
An Official ATS/ERS/JRS/ALAT C ...... 1 Clinical Practice Guideline.
@en
An Official ATS/ERS/JRS/ALAT C ...... 1 Clinical Practice Guideline.
@nl
P2093
P2860
P1476
An Official ATS/ERS/JRS/ALAT C ...... 1 Clinical Practice Guideline.
@en
P2093
Arata Azuma
Arthur Theodore
Athol U Wells
Bram Rochwerg
Carlos A Cuello Garcia
David Rind
European Respiratory society
Fernando J Martinez
Ganesh Raghu
Harold R Collard
P2860
P356
10.1164/RCCM.201506-1063ST
P407
P577
2015-07-01T00:00:00Z